These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24725538)

  • 21. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
    Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
    Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilomyxoid astrocytoma treated successfully with vemurafenib.
    Skrypek M; Foreman N; Guillaume D; Moertel C
    Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
    Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
    J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
    PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
    van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
    Beale S; Dickson R; Bagust A; Blundell M; Dundar Y; Boland A; Marshall E; Plummer R; Proudlove C
    Pharmacoeconomics; 2013 Dec; 31(12):1121-9. PubMed ID: 24114739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
    Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
    Mulcahy Levy JM; Foreman NK; Thorburn A
    Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
    Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
    Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
    Ceccon G; Werner JM; Dunkl V; Tscherpel C; Stoffels G; Brunn A; Deckert M; Fink GR; Galldiks N
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.